Phase 1Completed
A Safety Study of Orally Administered BPM31510 in Healthy Subjects
A Phase I Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Orally Administered BPM31510 in Healthy Subjects
- Sponsor
- BPGbio (Industry)
- Enrolment
- 25 enrolled
- Conditions
- Healthy
- Interventions
- BPM31510 Oral Nanosuspension 4%
- Ages
- adults, older adults
- Registry
- NCT03002935
From the registry
This is an open-label, Phase I study of the bioavailability and safety of BPM31510 administered orally in healthy subjects dosed 3 times daily for 14 days. The last study dose is administered on Day 15 (one morning dose only). The study will consist of 25 subjects.
Primary outcomes
- Maximum plasma concentration (Cmax)
- Area under the plasma concentration curve (AUC0-4)